Originally posted by soud:
↑
It is becoming increasingly clear to me that Australian branch is just a cash burner and will continue to be so. In fact, Cellmid has been making profit for quite sometime now without Australia. It is senseless to continue having the company's corporate office in Australia. It should be moved to Japan, CEO, Chairman and rest of the board to be released but retain David Ecks for his retail skills. Make the GM Japan the CEO and source out Japanese Chairman and Biotech Gurus from Japan as executive directors. This will create immediate significant profit margins and share prices will increase exponentially. Japan is closer to China and US. The later 2 will hence be better managed from Japan. As for Australia and New Zealand, just source local distributors for the Cellmid products or ship directly from Japan. This is a hairy audacious suggestions but if we remove our egos and let it go, it will definitely work. Both Chairman and CEO as substantial shareholders will be reaping the fruits as well.
Expand
Take a bow, Soud, well thought out and well done.
And it's not only Advangen which may benefit. Once the thickheads of the Buy/Held Trio thin out a bit, and the guffaws start to quiet down, they might start to think about the Nationality of many of the major researchers of Midkine.
